About this trial
The aim of the study is to investigate the confounding factors of chronic endometritis and therapeutic benefits of antibodies targeting plasma cells in women with reproductive failure.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 20-45 years;
Women with a history of 2 or more consecutive miscarriages before 24 weeks of gestation12; or
Women who failed to conceive after unprotected intercourse for one year; or
Women who failed failure to achieve a clinical pregnancy after two consecutive cycles of IVF, ICSI or frozen embryo replacement cycles where the cumulative number of transferred embryos is no less than four for day-2 embryos and no less than 2 for day-5 embryos (blastocysts), with all embryos being of good quality.
Disqualifiers
Uncorrected uterine anomalies, such as the septate or bicornuate uterus, fibroids (submucous/intramural);
Untreated hydrosalpinx;
History of antiphospholipid syndrome;
Known clinical autoimmune disease;
Trial population
Subjects will be identified and recruited from the IVF and miscarriage clinic by clinicians and research nurse.
Trial design
Cohort
Prospective
Treatments tested in this trial
- Other intervention
If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.
Treatment groups
Trial outcomes
Primary outcomes
Live birth rate
compare the brith rate between the group and cohort
Secondary outcomes
Compare the pregnancy rate between groups
compare the general pregnancy rate in women with or without CE
Compare the miscarriage rate between groups
compare the miscarriage rate in women with or without CE
Compare the implantation rate between groups
Compare the implantation successful rate in women with or without CE
Sponsors and contacts
Click on the lead sponsor to view all of their trials.